Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.62 |
| ▸ | NT5E | P21589 | 4/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156377 | 0.91 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156357 | 0.82 | ADORA3 (0.68) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10156393 | 0.81 | ADORA3 (0.55) | ADORA3NT5EADORA1ADORA2AADORA2B | |
| SCHEMBL13267604 | 0.80 | ADORA3 (0.46) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10156394 | 0.80 | ADORA3 (0.46) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10156410 | 0.80 | ADORA3 (0.70) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL13267605 | 0.80 | ADORA3 (0.70) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10157116 | 0.79 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10157154 | 0.79 | ADORA3 (0.63) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6660843 | 0.78 | ADORA3 (0.81) | ADORA3NT5EADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | ADORA3 1044/4885NT5E 4517/4885ADORA1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.